5-FU based doublet chemotherapy + bevacizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Colorectal Cancer
Conditions
Colorectal Cancer
Trial Timeline
Oct 16, 2012 → May 12, 2016
NCT ID
NCT01695772About 5-FU based doublet chemotherapy + bevacizumab
5-FU based doublet chemotherapy + bevacizumab is a approved stage product being developed by Roche for Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01695772. Target conditions include Colorectal Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01695772 | Approved | Completed |
Competing Products
20 competing products in Colorectal Cancer